The true cost of pharmacological disease preventiion.pdf

The true cost of pharmacological disease preventiion.pdf -...

Info icon This preview shows pages 1–2. Sign up to view the full content.

The true cost of pharmacological disease prevention Despite widespread use of preventive drugs such as statins, antihypertensives, and bisphosphonates, there is no valid evidence that they represent value for money, argue Teppo Järvinen and colleagues Teppo L N Järvinen orthopaedic resident 1 2 , Harri Sievänen research director 3 , Pekka Kannus chief physician 4 , Jarkko Jokihaara postdoctoral fellow 5 , Karim M Khan professor 5 1 Department of Orthopaedic Surgery, University of Tampere, 33014 Tampere, Finland; 2 Department of Surgery, Central Finland Central Hospital, 40620 Jyväskylä, Finland; 3 Bone Research Group, UKK-Institute, 33500 Tampere; 4 Division of Orthopaedics and Traumatology, Tampere University Hospital, 33520 Tampere; 5 Centre for Hip Health and Mobility, University of British Columbia, Vancouver, British Columbia, Canada Large randomised clinical trials are considered to represent the strongest form of evidence in assessing whether a particular healthcare intervention works. However, little attention has been paid to the fact that people treated in large multicentre randomised trials may not accurately reflect the population receiving the drug in real world settings. 1 Recently, van Staa and colleagues assessed the external validity of published cost effectiveness studies of selective cyclo-oxygenase-2 (COX 2) inhibitors by comparing the data used in these studies (typically from randomised trials) with observed clinical data. 2 The trial data suggested that the cost of avoiding one adverse gastrointestinal event by switching patients from conventional non-steroidal anti-inflammatory drugs to COX 2 inhibitors would be about $20 000 (£12 500; €14 000). However, when the same analysis was performed using the UK’s General Practice Research Database, comprising anonymised medical records of general practitioners, the cost of preventing one bleed was fivefold greater ($104 000). 2 The authors concluded that the published cost effectiveness analyses of COX 2 inhibitors neither had external validity nor represented the patients treated in clinical practice. They emphasised that external validity should be an explicit requirement for cost effectiveness analyses that are used to guide treatment policies and practices. Efficacy versus effectiveness This striking difference between the results from randomised trials and the real world clinical implications was recognised by Archie Cochrane, the pioneering clinical epidemiologist. Almost 40 years ago, Professor Cochrane introduced a specific hierarchy of evidence required from any healthcare intervention before it can be applied to real life situations (table). Three simple questions summarise Cochrane’s scheme: can it work (efficacy)? does it work (effectiveness)? and is it worth it (cost effectiveness)?
Image of page 1

Info icon This preview has intentionally blurred sections. Sign up to view the full version.

Image of page 2
This is the end of the preview. Sign up to access the rest of the document.
  • Spring '18
  • Jennifer Schnellmann
  • Clinical trial, Randomized controlled trial, Hip fracture

{[ snackBarMessage ]}

What students are saying

  • Left Quote Icon

    As a current student on this bumpy collegiate pathway, I stumbled upon Course Hero, where I can find study resources for nearly all my courses, get online help from tutors 24/7, and even share my old projects, papers, and lecture notes with other students.

    Student Picture

    Kiran Temple University Fox School of Business ‘17, Course Hero Intern

  • Left Quote Icon

    I cannot even describe how much Course Hero helped me this summer. It’s truly become something I can always rely on and help me. In the end, I was not only able to survive summer classes, but I was able to thrive thanks to Course Hero.

    Student Picture

    Dana University of Pennsylvania ‘17, Course Hero Intern

  • Left Quote Icon

    The ability to access any university’s resources through Course Hero proved invaluable in my case. I was behind on Tulane coursework and actually used UCLA’s materials to help me move forward and get everything together on time.

    Student Picture

    Jill Tulane University ‘16, Course Hero Intern